FMC Corporation (FMC) announced its 2026 operational priorities and a bold decision by its Board of Directors to explore strategic options - including a potential sale of the company. The announcement came alongside the release of Q4 and full-year 2025 results, which showed declines in revenue and profitability.

This matters because FMC is a global player in crop protection, and its actions send signals across the agchem market, from farmers and co-ops to policy makers and investors. The company faces challenges related to post-patent pricing pressure, geographic portfolio reshaping, and a need to strengthen its balance sheet.

FMC will aim to pay down $1 billion in debt, mainly through asset sales and licensing deals, including the already-announced exit from India's commercial business.

The strategy focuses on:

• Improving competitiveness of its legacy product portfolio

• Managing the Rynaxypyr® post-patent transition

• Accelerating commercialization of new active ingredients:

  • Isoflex® active

  • Fluindapyr

  • Dodhylex® active

  • Rimisoxafen

CEO Pierre Brondeau emphasized that the company's long-term value lies in its innovation pipeline and that a strategic review could unlock growth via partnerships, investment, or other structural changes.

"We're focused on balance sheet strength and portfolio competitiveness while evaluating strategic options to deliver long-term shareholder value," said Brondeau.

FMC expects 2026 revenue to fall 5%, with adjusted EBITDA down 17% and EPS down 41%. While new active ingredients are projected to grow over 75%, pricing pressure - particularly on Rynaxypyr® - and the removal of India will drag down performance.

Full Year and Q1 2026 Guidance

India has been excluded from 2026 guidance.

FMC reported $3.47 billion in 2025 revenue, an 18% decline from 2024. Excluding India, the drop was 8%. Lower pricing - especially from competitive pressures and partner contract adjustments - drove the decline. Still, volume grew 1%, supported by Brazil and new product launches.

Like-for-Like Revenue Trends

FMC booked a $1.72 billion goodwill impairment in Q4, resulting in a GAAP net loss of $13.74 per share. Adjusted EPS for Q4 was $1.20, down 33% year over year.

Latin America and North America remained the largest contributors, while India posted a $421.9M loss as it was reclassified as a held-for-sale asset.

FMC Regional Revenue (USD Millions)

Sales of fluindapyr, Isoflex® and Dodhylex® hit $200 million in 2025, growing 54% year over year, though short of the $250M target. FMC blamed registration delays in the UK and other timing factors.

Why This Matters to U.S. Ag Professionals

FMC's moves impact:

• Commodity markets and input pricing

• Retailer and co-op strategies

• Farmer access to innovative products

• Investor confidence in agchem sector

• Global crop protection supply chains

As a key supplier to U.S. agriculture, FMC's pricing decisions and product launches ripple through the ag value chain, particularly as sustainability and ROI pressures intensify.

• FMC will be a player in transition in 2026.

• Expect a shifting product mix, reduced exposure to India, and more reliance on post-patent strategy execution.

• The company's R&D pipeline remains valuable, but structural changes may redefine how it delivers innovation to market.